ArticleThe Permanente journal2017
Induction with Infliximab and a Plant-Based Diet as First-Line (IPF) Therapy for Crohn Disease: A Single-Group Trial.
Article in The Permanente journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Pooled it
- Nutritional interventions in adult fibrostenotic Crohn's disease: A systematic review.Frontiers in nutrition · 2023Pooled it
- High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial.The Permanente journal · 2020Trial
- Relapse Prevention by Plant-Based Diet Incorporated into Induction Therapy for Ulcerative Colitis: A Single-Group Trial.The Permanente journal · 2019Trial
- Food-Based Therapies in Pediatric Inflammatory Bowel Diseases.Nutrients · 2026Review
- Whole-food diet therapies for children with Crohn's disease: a systematic review.Therapeutic advances in gastroenterology · 2025Review
- The role of plant-based dietary compounds in gut microbiota modulation in inflammatory bowel disease.Frontiers in nutrition · 2025Review
- Long-term durability of infliximab maintenance therapy incorporating plant-based diet in inflammatory bowel disease.Translational gastroenterology and hepatology · 2025Article
- Plant-Based Diet Recommended for Inflammatory Bowel Disease.Inflammatory bowel diseases · 2023Article
- Incorporation of Plant-Based Diet Surpasses Current Standards in Therapeutic Outcomes in Inflammatory Bowel Disease.Metabolites · 2023Review
- British Dietetic Association consensus guidelines on the nutritional assessment and dietary management of patients with inflammatory bowel disease.Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 2023Article
- Therapeutic advancement in inflammatory bowel disease by incorporating plant-based diet.Translational gastroenterology and hepatology · 2023Review
- Dietary Patterns and Gut Microbiota: The Crucial Actors in Inflammatory Bowel Disease.Advances in nutrition (Bethesda, Md.) · 2022Review
- Dietary Patterns and Gut Microbiota Changes in Inflammatory Bowel Disease: Current Insights and Future Challenges.Nutrients · 2022Review
- Relapse-Free Course in Nearly Half of Crohn's Disease Patients With Infliximab and Plant-Based Diet as First-Line Therapy: A Single-Group Trial.The Permanente journal · 2022Article
- Food Additives, a Key Environmental Factor in the Development of IBD through Gut Dysbiosis.Microorganisms · 2022Review
- Stepwise Treatment With Plant-Based Diet and Medication for Patient With Mild Ulcerative Colitis.The Permanente journal · 2021Article
- Increased Incidence of Inflammatory Bowel Disease in Association with Dietary Transition (Westernization) in Japan.JMA journal · 2021Article
- Let Food Be Thy Medicine-Its Role in Crohn's Disease.Nutrients · 2021Review
- Dietary Composition and Effects in Inflammatory Bowel Disease.Nutrients · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproximately 30% of patients with Crohn disease (CD) are unresponsive to biologics. No previous study has focused on a plant-based diet in an induction phase of CD treatment.
objectiveTo investigate the remission rate of infliximab combined with a plant-based diet as first-line (IPF) therapy for CD.
methodsThis was a prospective single-group trial conducted at tertiary hospitals. Subjects included consecutive adults with a new diagnosis (n = 26), children with a new diagnosis (n = 11), and relapsing adults (n = 9) with CD who were naïve to treatment with biologics. Patients were admitted and administered a standard induction therapy with infliximab (5 mg/kg; 3 infusions at 0, 2, and 6 weeks). Additionally, they received a lacto-ovo-semivegetarian diet. The primary end point was remission, defined as the disappearance of active CD symptoms at week 6. Secondary end points were Crohn Disease Activity Index (CDAI) score, C-reactive protein (CRP) concentration, and mucosal healing.
resultsTwo adults with a new diagnosis were withdrawn from the treatment protocol because of intestinal obstruction. The remission rates by the intention-to-treat and per-protocol analyses were 96% (44/46) and 100% (44/44), respectively. Mean CDAI score (314) on admission decreased to 63 at week 6 (p < 0.0001). Mean CRP level on admission (5.3 mg/dL) decreased to 0.2 (p < 0.0001). Mucosal healing was achieved in 46% (19/41) of cases.
conclusionIPF therapy can induce remission in most patients with CD who are naïve to biologics regardless of age or whether they have a new diagnosis or relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.